Prelude Therapeutics Stock Z Score
| PRLD Stock | USD 0.75 0.01 1.35% |
Prelude | Z Score |
Prelude Therapeutics Company Z Score Analysis
Prelude Therapeutics' Z-Score is a simple linear, multi-factor model that measures the financial health and economic stability of a company. The score is used to predict the probability of a firm going into bankruptcy within next 24 months or two fiscal years from the day stated on the accounting statements used to calculate it. The model uses five fundamental business ratios that are weighted according to algorithm of Professor Edward Altman who developed it in the late 1960s at New York University..
| |||||||
| |||||||
| |||||||
| |||||||
|
Prelude Z Score Driver Correlations
Understanding the fundamental principles of building solid financial models for Prelude Therapeutics is extremely important. It helps to project a fair market value of Prelude Stock properly, considering its historical fundamentals such as Z Score. Since Prelude Therapeutics' main accounts across its financial reports are all linked and dependent on each other, it is essential to analyze all possible correlations between related accounts. However, instead of reviewing all of Prelude Therapeutics' historical financial statements, investors can examine the correlated drivers to determine its overall health. This can be effectively done using a conventional correlation matrix of Prelude Therapeutics' interrelated accounts and indicators.
Click cells to compare fundamentals
To calculate a Z-Score, one would need to know a company's current working capital, its total assets and liabilities, and the amount of its latest earnings as well as earnings before interest and tax. Z-Scores can be used to compare the odds of bankruptcy of companies in a similar line of business or firms operating in the same industry. Companies with Z-Scores above 3.1 are generally considered to be stable and healthy with a low probability of bankruptcy. Scores that fall between 1.8 and 3.1 lie in a so-called 'grey area,' with scores of less than 1 indicating the highest probability of distress. Z Score is a used widely measure by financial auditors, accountants, money managers, loan processors, wealth advisers, and day traders. In the last 25 years, many financial models that utilize z-scores proved it to be successful as a predictor of corporate bankruptcy.
| Competition |
Based on the company's disclosures, Prelude Therapeutics has a Z Score of 0.0. This is 100.0% lower than that of the Biotechnology sector and 100.0% lower than that of the Health Care industry. The z score for all United States stocks is 100.0% higher than that of the company.
Prelude Z Score Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Prelude Therapeutics' direct or indirect competition against its Z Score to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Prelude Therapeutics could also be used in its relative valuation, which is a method of valuing Prelude Therapeutics by comparing valuation metrics of similar companies.Prelude Therapeutics is currently under evaluation in z score category among its peers.
Prelude Therapeutics Current Valuation Drivers
We derive many important indicators used in calculating different scores of Prelude Therapeutics from analyzing Prelude Therapeutics' financial statements. These drivers represent accounts that assess Prelude Therapeutics' ability to generate profits relative to its revenue, operating costs, and shareholders' equity. Below are some of Prelude Therapeutics' important valuation drivers and their relationship over time.
| 2020 | 2021 | 2022 | 2023 | 2024 | 2025 (projected) | ||
| Market Cap | 3.1B | 592.6M | 286.1M | 257.7M | 96.3M | 91.5M | |
| Enterprise Value | 2.9B | 562.6M | 257.4M | 249.3M | 101.8M | 96.7M |
Prelude Therapeutics Institutional Holders
Institutional Holdings refers to the ownership stake in Prelude Therapeutics that is held by large financial organizations, pension funds or endowments. Institutions may purchase large blocks of Prelude Therapeutics' outstanding shares and can exert considerable influence upon its management. Institutional holders may also work to push the share price higher once they own the stock. Extensive social media coverage, TV shows, articles in high-profile magazines, and presentations at investor conferences help move the stock higher, increasing Prelude Therapeutics' value.| Shares | Geode Capital Management, Llc | 2024-12-31 | 402.3 K | Marshall Wace Asset Management Ltd | 2024-12-31 | 392.2 K | Morgan Stanley - Brokerage Accounts | 2024-12-31 | 365.2 K | Two Sigma Advisers, Llc | 2024-12-31 | 300 K | State Street Corp | 2024-12-31 | 293.4 K | Two Sigma Investments Llc | 2024-12-31 | 231.8 K | Rhumbline Advisers | 2024-12-31 | 166.8 K | Td Asset Management Inc | 2024-12-31 | 160.7 K | Goldman Sachs Group Inc | 2024-12-31 | 148.3 K | Orbimed Advisors, Llc | 2024-12-31 | 10.9 M | Baker Bros Advisors Lp | 2024-12-31 | 10.1 M |
Prelude Fundamentals
| Return On Equity | -0.69 | ||||
| Return On Asset | -0.39 | ||||
| Operating Margin | (8.46) % | ||||
| Current Valuation | (74.51 M) | ||||
| Shares Outstanding | 42.3 M | ||||
| Shares Owned By Insiders | 7.19 % | ||||
| Shares Owned By Institutions | 68.77 % | ||||
| Number Of Shares Shorted | 3.1 M | ||||
| Price To Book | 0.31 X | ||||
| Price To Sales | 5.87 X | ||||
| Revenue | 7 M | ||||
| Gross Profit | 7 M | ||||
| EBITDA | (139.71 M) | ||||
| Net Income | (127.17 M) | ||||
| Cash And Equivalents | 246.3 M | ||||
| Cash Per Share | 5.19 X | ||||
| Total Debt | 18.02 M | ||||
| Debt To Equity | 0.01 % | ||||
| Current Ratio | 15.73 X | ||||
| Book Value Per Share | 2.38 X | ||||
| Cash Flow From Operations | (102.89 M) | ||||
| Short Ratio | 11.06 X | ||||
| Earnings Per Share | (1.68) X | ||||
| Price To Earnings To Growth | (0.09) X | ||||
| Target Price | 3.33 | ||||
| Number Of Employees | 131 | ||||
| Beta | 1.42 | ||||
| Market Capitalization | 41.08 M | ||||
| Total Asset | 175.51 M | ||||
| Retained Earnings | (583.56 M) | ||||
| Working Capital | 110.25 M | ||||
| Net Asset | 175.51 M |
About Prelude Therapeutics Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Prelude Therapeutics's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Prelude Therapeutics using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Prelude Therapeutics based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.When determining whether Prelude Therapeutics is a strong investment it is important to analyze Prelude Therapeutics' competitive position within its industry, examining market share, product or service uniqueness, and competitive advantages. Beyond financials and market position, potential investors should also consider broader economic conditions, industry trends, and any regulatory or geopolitical factors that may impact Prelude Therapeutics' future performance. For an informed investment choice regarding Prelude Stock, refer to the following important reports:Check out Prelude Therapeutics Piotroski F Score and Prelude Therapeutics Valuation analysis. For information on how to trade Prelude Stock refer to our How to Trade Prelude Stock guide.You can also try the Risk-Return Analysis module to view associations between returns expected from investment and the risk you assume.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Prelude Therapeutics. If investors know Prelude will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Prelude Therapeutics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
The market value of Prelude Therapeutics is measured differently than its book value, which is the value of Prelude that is recorded on the company's balance sheet. Investors also form their own opinion of Prelude Therapeutics' value that differs from its market value or its book value, called intrinsic value, which is Prelude Therapeutics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Prelude Therapeutics' market value can be influenced by many factors that don't directly affect Prelude Therapeutics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Prelude Therapeutics' value and its price as these two are different measures arrived at by different means. Investors typically determine if Prelude Therapeutics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Prelude Therapeutics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.